LLY
Eli Lilly and Company
LLY has the edge over SGRY overall, supported by stronger fundamentals and lower modeled downside.
SGRY
Surgery Partners, Inc.
SGRY trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SGRY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Weak |
SGRY's revenue, profitability and cash flow are currently stable, but its balance sheet is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SGRY PE Valuation
SGRY has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over SGRY on the outlook, with more favorable earnings and revenue expectations.
SGRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect SGRY's revenue and profitability to decline, with its earnings holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SGRY on earnings quality, reporting a profit while its opponent remains loss making.
SGRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | — |
| Q3 2026 | -$0.67 | +$0.69 |
| Q2 2026 | -$0.69 | +$0.74 |
| Q1 2026 | -$0.59 | +$0.94 |
| Q4 2025 | -$0.61 | +$0.72 |
| Q3 2025 | -$1.36 | -$0.89 |
| Q2 2025 | -$1.43 | -$1.17 |
| Q1 2025 | -$1.53 | -15400% |
| Q4 2024 | -$1.33 | -$1.24 |
SGRY is still losing money, but far less than before: $0.67 per share over the past year, against $3.67 at its worst in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SGRY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SGRY on profitability, with a higher operating margin.
SGRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $815.3M | -0.8% |
| Q2 2026 | $848.9M | +2.7% |
| Q1 2026 | $810.9M | +4.5% |
| Q4 2025 | $885M | +2.4% |
| Q3 2025 | $821.5M | +6.6% |
| Q2 2025 | $826.2M | +8.4% |
| Q1 2025 | $776M | +8.2% |
| Q4 2024 | $864.4M | +18% |
SGRY's revenue grew through 2024 and has held roughly level since: $815M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -2.4 points |
| Q2 2026 | 12% | -1.5 points |
| Q1 2026 | 8.1% | +0.1 points |
| Q4 2025 | 12% | -2.3 points |
| Q3 2025 | 13% | +5 points |
| Q2 2025 | 14% | +2.4 points |
| Q1 2025 | 8% | -2.6 points |
| Q4 2024 | 15% | +0.9 points |
SGRY's operating margin was 11% last quarter, down 2.4 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
SGRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $79M | +24% |
| Q2 2026 | $37.5M | -35% |
| Q1 2026 | -$4.3M | +$12.4M |
| Q4 2025 | $90.6M | +1.7% |
| Q3 2025 | $63.8M | +42% |
| Q2 2025 | $57.9M | +3.6% |
| Q1 2025 | -$16.7M | -185% |
| Q4 2024 | $89.1M | +108% |
SGRY generated $203M in free cash flow over the past year, up 4.5% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SGRY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SGRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +40K shares |
| 1 year | +1.3% | +1.7M shares |
| 3 years | +2.5% | +3.1M shares |
| 5 years | +86% | +59.6M shares |
| Available history | +167% | +80.6M shares |
SGRY has 129M diluted shares, up 1.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over SGRY on leverage, with a lower net debt burden relative to earnings.
SGRY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.0x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 6.2x | High |
| Q4 2025 | 6.1x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 6.4x | High |
| Q1 2025 | 6.8x | High |
| Q4 2024 | 6.2x | High |
SGRY's net debt is about 5.0 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SGRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.5 | Overbought |
| Stochastic | 97.4 | Overbought |
SGRY's weekly RSI is 79 (overbought) and its Stochastic is 97 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SGRY PE vs Healthcare Sector
| Metric | SGRY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SGRY has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
SGRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.1 | 47% above |
| 20 week MA | $16.3 | 63% above |
| 50 week MA | $15.2 | 75% above |
| 100 week MA | $18.6 | 43% above |
| 200 week MA | $25.0 | 6.5% above |
SGRY has climbed back above all five of its weekly moving averages, and it's now 6.5% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
SGRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.5 | $27.8 | +79% |
| 2021 | $27.8 | $53.5 | +92% |
| 2022 | $53.5 | $26.7 | -50% |
| 2023 | $26.7 | $32.0 | +20% |
| 2024 | $32.0 | $20.9 | -35% |
| 2025 | $20.9 | $15.9 | -24% |
| 2026 YTD | $15.9 | $26.6 | +67% |
SGRY has the edge over LLY on returns for 2026, with the stronger performance.